Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 11:59 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 13,738 matching trials from the live ClinicalTrials.gov search.

Filters: Baltimore, Maryland Clear all

Conditions: Primary Sjögren's Syndrome
Interventions: Baminercept, Placebo; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 9
States / cities: Los Angeles, California • Palo Alto, California • Hartford, Connecticut + 6 more

Conditions: Thromboembolism
Interventions: dabigatran etexilate 150 mg, warfarin (INR 2-3); Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 2,564 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 23
States / cities: Mobile, Alabama • Hartford, Connecticut • Clearwater, Florida + 19 more

Conditions: Craniectomy, Trephined Syndrome, Traumatic Brain Injury (TBI) Patients, Ischemic Stroke
Interventions: External Cranial Prosthesis; Device
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: Scleroderma, Raynaud's Syndrome
Interventions: Onabotulinumtoxin A, sterile saline solution; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Metastatic Bone Disease
Interventions: Internal Fixation, Resection and reconstruction; Procedure
Lead sponsor: Michelle Ghert, MD; Other
Eligibility: 18 Years and older
Enrollment: 334 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 7
States / cities: Aurora, Colorado • Fort Wayne, Indiana • Baltimore, Maryland + 4 more

Conditions: Renal Cell Carcinoma
Interventions: Combination of Temsirolimus and Sunitinib; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 4
States / cities: Baltimore, Maryland • Boston, Massachusetts • New York, New York + 1 more

Conditions: Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I)
Interventions: BBP-418 (ribitol); Drug
Lead sponsor: ML Bio Solutions, Inc.; Industry
Eligibility: Not listed
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 12
States / cities: Little Rock, Arkansas • Orange, California • Aurora, Colorado + 8 more

Conditions: Asthma
Interventions: VR506, Placebo; Drug
Lead sponsor: Vectura Limited; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 374 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 32
States / cities: Fountain Valley, California • Los Angeles, California • Mission Viejo, California + 28 more

Conditions: HIV Infections
Interventions: Indinavir sulfate, Abacavir sulfate, Amprenavir, Nelfinavir mesylate, Efavirenz, Levocarnitine, Adefovir dipivoxil, Saquinavir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 475 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2000
U.S. locations: 44
States / cities: Los Angeles, California • Menlo Park, California • San Diego, California + 27 more

Conditions: Head and Neck Cancer, Oral Complications, Radiation Toxicity
Interventions: cevimeline hydrochloride; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 71
States / cities: Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 61 more

Conditions: HIV Infections
Interventions: Alovudine; Drug
Lead sponsor: Lederle Laboratories; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Respiratory Syncytial Virus (RSV)
Interventions: RSVpreF Vaccine; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 440 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 17
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Decatur, Georgia + 8 more

Conditions: Chronic Myelogenous Leukemia in Chronic Phase
Interventions: Nilotinib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 32
States / cities: Anaheim, California • Burbank, California • Concord, California + 27 more

Conditions: HIV Infections, Pregnancy
Interventions: Lamivudine, Lamivudine/Zidovudine, Nelfinavir mesylate, Nevirapine, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 14 Years and older · Female only
Enrollment: 440 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 44
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 28 more

Conditions: Macular Degeneration
Interventions: ranibizumab, aflibercept injection (VEGF Trap-Eye, BAY86-5321); Biological
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 50 Years and older
Enrollment: 1,217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 176
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 144 more

Conditions: Leukemia
Interventions: Dasatinib, BMS-833923; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 3
States / cities: San Francisco, California • Baltimore, Maryland • Houston, Texas

Conditions: Breast Carcinoma, Recurrent Breast Carcinoma, Stage IV Breast Cancer
Interventions: Bevacizumab, Carboplatin, Paclitaxel, Placebo, Trastuzumab; Biological · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2015
U.S. locations: 373
States / cities: Jonesboro, Arkansas • Castro Valley, California • Emeryville, California + 236 more

Conditions: Migraine
Interventions: Fremanezumab, Placebo; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 235 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 45
States / cities: Little Rock, Arkansas • Banning, California • Loma Linda, California + 38 more

Conditions: Chronic Hepatitis C
Interventions: Debio 025, Peg-IFNα2a, Ribavirin; Drug
Lead sponsor: Debiopharm International SA; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 7
States / cities: La Jolla, California • Gainesville, Florida • Miami, Florida + 4 more

Conditions: Chronic Spontaneous Urticaria
Interventions: barzolvolimab, Standard of Care; Biological · Other
Lead sponsor: Celldex Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 1,370 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 45
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Bakersfield, California + 39 more

Conditions: Lung Cancer
Interventions: carboplatin, gemcitabine hydrochloride, paclitaxel; Drug
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001
U.S. locations: 57
States / cities: Loma Linda, California • Pomona, California • New London, Connecticut + 46 more

Conditions: COPD (Chronic Obstructive Pulmonary Disease)
Interventions: Indacaterol/Glycopyrrolate, Placebo; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 40 Years to 80 Years
Enrollment: 780 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 16
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 12 more

Conditions: Kidney Transplantation
Interventions: AEB071; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 23
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 17 more

Conditions: Neoplasm
Interventions: PTK787/ZK222584; Drug
Lead sponsor: Pancreatic Cancer Research Team; Other
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 7
States / cities: Scottsdale, Arizona • Tucson, Arizona • Beverly Hills, California + 4 more

Search by objective public record fields.

Baminercept, a Lymphotoxin-Beta Receptor Fusion Protein, for Treatment of Sjögren's Syndrome

Efficacy and Safety of Dabigatran Compared to Warfarin for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism

External Post-Operative Skull Prosthesis to Prevent Sunken Flap Syndrome in Craniectomy Patients

Efficacy of Botulinum Toxin In Scleroderma-Associated Raynaud's Syndrome

Proximal FEmur Reconstruction or Internal Fixation fOR Metastases (PERFORM) Trial

A Study Combining Treatment With Temsirolimus and Sunitinib for Subjects With Advanced Renal Cell Carcinoma

Open-Label Extension Study of BBP-418 (Ribitol) for LGMD2I/R9

Clinical Study to Evaluate the Efficacy of VR506 Using a New Inhaler for the Treatment of Asthma

A Study on Amprenavir in Combination With Other Anti-HIV Drugs in HIV-Positive Patients

Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer

An Ascending, Single Oral Dose Pharmacokinetic Study of 3'-Deoxy-3'-Fluorothymidine (FLT) in Asymptomatic Human Immunodeficiency Virus (HIV)-Infected Subjects

A Study to Learn About Revaccination With a Vaccine Called RSVpreF in Immunocompromised Adults

CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib

Combination Treatment With and Without Protease Inhibitors for Women Who Begin Therapy for HIV Infection During Pregnancy

Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD)

Dasatinib Combination Therapy With the Smoothened (SMO) Inhibitor BMS-833923 in Chronic Myeloid Leukemia (CML)

Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU

A Study to Test if Fremanezumab is Effective in Preventing Episodic Migraine in Patients 6 to 17 Years of Age

A Study of Debio 025 in Combination With PegIFN Alpha-2a and Ribavirin in Chronic HCV Patients Non-responders to Standard Treatment

Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria

Combination Chemotherapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

RETHINC: REdefining THerapy In Early COPD for the Pulmonary Trials Cooperative

Efficacy and Safety of AEB071 Versus Tacrolimus in Combination With Mycophenolate Acid Sodium, Basiliximab and Steroids in Preventing Acute Rejection After Kidney Transplantation

PTK787 in Patients With Advanced Metastatic Pancreatic Adenocarcinoma